Rhythm Pharmaceuticals (RYTM) Competitors $91.98 -0.50 (-0.54%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$91.96 -0.03 (-0.03%) As of 08/8/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. INSM, SMMT, TEVA, GMAB, RDY, QGEN, MRNA, ASND, VTRS, and BBIOShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Its Competitors Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Rhythm Pharmaceuticals (NASDAQ:RYTM) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations. Do analysts recommend RYTM or INSM? Rhythm Pharmaceuticals currently has a consensus price target of $101.57, suggesting a potential upside of 10.43%. Insmed has a consensus price target of $112.71, suggesting a potential upside of 2.89%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Insmed 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RYTM or INSM more profitable? Rhythm Pharmaceuticals has a net margin of -117.13% compared to Insmed's net margin of -259.82%. Insmed's return on equity of -195.37% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-117.13% -1,831.43% -48.33% Insmed -259.82%-195.37%-49.49% Which has more volatility & risk, RYTM or INSM? Rhythm Pharmaceuticals has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Does the media favor RYTM or INSM? In the previous week, Rhythm Pharmaceuticals had 9 more articles in the media than Insmed. MarketBeat recorded 23 mentions for Rhythm Pharmaceuticals and 14 mentions for Insmed. Rhythm Pharmaceuticals' average media sentiment score of 0.69 beat Insmed's score of 0.56 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Insmed 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, RYTM or INSM? Rhythm Pharmaceuticals has higher earnings, but lower revenue than Insmed. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M46.95-$260.60M-$3.01-30.56Insmed$363.71M63.67-$913.77M-$5.95-18.41 SummaryRhythm Pharmaceuticals beats Insmed on 10 of the 15 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.11B$2.99B$5.47B$9.71BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-30.5617.3230.1024.70Price / Sales46.95326.67458.19100.35Price / CashN/A40.7324.8428.01Price / Book262.808.888.525.76Net Income-$260.60M-$54.75M$3.27B$267.05M7 Day Performance1.93%-2.07%4.65%3.13%1 Month Performance6.09%1.81%0.96%1.27%1 Year Performance103.23%8.71%36.43%22.83% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals3.996 of 5 stars$91.98-0.5%$101.57+10.4%+103.2%$6.11B$130.13M-30.56140Earnings ReportAnalyst RevisionINSMInsmed3.9262 of 5 stars$111.24+2.3%$109.20-1.8%+48.1%$20.62B$363.71M-18.701,271Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics1.9913 of 5 stars$29.32+8.3%$34.67+18.2%+165.9%$20.10B$700K-86.23110Upcoming EarningsTEVATeva Pharmaceutical Industries2.9484 of 5 stars$15.70+2.1%$24.71+57.4%-6.3%$17.64B$16.54B-98.1336,830Positive NewsGMABGenmab A/S3.6943 of 5 stars$21.98+0.9%$37.80+72.0%-18.9%$13.97B$3.12B12.492,682Trending NewsEarnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories2.5352 of 5 stars$13.80-1.0%$16.95+22.9%-17.7%$11.64B$334.26B20.9027,811QGENQiagen3.5547 of 5 stars$50.27+0.7%$49.40-1.7%+8.7%$11.10B$1.98B126.045,765Earnings ReportAnalyst DowngradeAnalyst RevisionMRNAModerna4.4694 of 5 stars$27.64+0.1%$45.61+65.0%-69.2%$10.68B$3.24B-3.675,800ASNDAscendis Pharma A/S3.4178 of 5 stars$184.15+5.5%$223.67+21.5%+50.8%$10.67B$393.54M-29.321,017Trending NewsEarnings ReportAnalyst ForecastVTRSViatris1.7946 of 5 stars$8.94+1.5%$10.40+16.3%-17.7%$10.34B$14.74B-2.8232,000Trending NewsEarnings ReportDividend AnnouncementAnalyst UpgradeBBIOBridgeBio Pharma4.7287 of 5 stars$47.75+0.8%$61.18+28.1%+90.7%$8.99B$221.90M-13.53400Trending NewsEarnings ReportAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Insmed Competitors Summit Therapeutics Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Qiagen Competitors Moderna Competitors Ascendis Pharma A/S Competitors Viatris Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale